365 related articles for article (PubMed ID: 26291246)
1. Interplay between promoter methylation and chromosomal loss in gene silencing at 3p11-p14 in cervical cancer.
Lando M; Fjeldbo CS; Wilting SM; C Snoek B; Aarnes EK; Forsberg MF; Kristensen GB; Steenbergen RD; Lyng H
Epigenetics; 2015; 10(10):970-80. PubMed ID: 26291246
[TBL] [Abstract][Full Text] [Related]
2. Hypermethylation of the tumor suppressor gene RASSFIA and frequent concomitant loss of heterozygosity at 3p21 in cervical cancers.
Yu MY; Tong JH; Chan PK; Lee TL; Chan MW; Chan AW; Lo KW; To KF
Int J Cancer; 2003 Jun; 105(2):204-9. PubMed ID: 12673680
[TBL] [Abstract][Full Text] [Related]
3. [Correlation between methylation of 5'-CpG islands and inactivation of FHIT gene in cervical cancer].
Shi HR; Wu QH; Suo ZH; Nesland JM
Ai Zheng; 2005 Jan; 24(1):7-11. PubMed ID: 15642192
[TBL] [Abstract][Full Text] [Related]
4. Exploring breast carcinogenesis through integrative genomics and epigenomics analyses.
Minning C; Mokhtar NM; Abdullah N; Muhammad R; Emran NA; Ali SA; Harun R; Jamal R
Int J Oncol; 2014 Nov; 45(5):1959-68. PubMed ID: 25175708
[TBL] [Abstract][Full Text] [Related]
5. Hypermethylation and loss of heterozygosity of tumor suppressor genes on chromosome 3p in cervical cancer.
Choi CH; Lee KM; Choi JJ; Kim TJ; Kim WY; Lee JW; Lee SJ; Lee JH; Bae DS; Kim BG
Cancer Lett; 2007 Sep; 255(1):26-33. PubMed ID: 17467893
[TBL] [Abstract][Full Text] [Related]
6. Promoter hypermethylation of the tumor-suppressor genes RASSF1A, GSTP1 and CDH1 in endometrial cancer.
Fiolka R; Zubor P; Janusicova V; Visnovsky J; Mendelova A; Kajo K; Lasabova Z; Plank L; Danko J
Oncol Rep; 2013 Dec; 30(6):2878-86. PubMed ID: 24068440
[TBL] [Abstract][Full Text] [Related]
7. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
[TBL] [Abstract][Full Text] [Related]
8. Aberrant promoter methylation and silencing of the POU2F3 gene in cervical cancer.
Zhang Z; Huettner PC; Nguyen L; Bidder M; Funk MC; Li J; Rader JS
Oncogene; 2006 Aug; 25(39):5436-45. PubMed ID: 16607278
[TBL] [Abstract][Full Text] [Related]
9. DNA methylation regulated microRNAs in human cervical cancer.
Varghese VK; Shukla V; Kabekkodu SP; Pandey D; Satyamoorthy K
Mol Carcinog; 2018 Mar; 57(3):370-382. PubMed ID: 29077234
[TBL] [Abstract][Full Text] [Related]
10. The role of ADCYAP1, adenylate cyclase activating polypeptide 1, as a methylation biomarker for the early detection of cervical cancer.
Jung S; Yi L; Jeong D; Kim J; An S; Oh TJ; Kim CH; Kim CJ; Yang Y; Kim KI; Lim JS; Lee MS
Oncol Rep; 2011 Jan; 25(1):245-52. PubMed ID: 21109983
[TBL] [Abstract][Full Text] [Related]
11. Methylomics analysis identifies epigenetically silenced genes and implies an activation of β-catenin signaling in cervical cancer.
Chen YC; Huang RL; Huang YK; Liao YP; Su PH; Wang HC; Chang CC; Lin YW; Yu MH; Chu TY; Lai HC
Int J Cancer; 2014 Jul; 135(1):117-27. PubMed ID: 24310984
[TBL] [Abstract][Full Text] [Related]
12. Promoter methylation status of the FHIT gene and Fhit expression: association with HER2/neu status in breast cancer patients.
Jeong YJ; Jeong HY; Lee SM; Bong JG; Park SH; Oh HK
Oncol Rep; 2013 Nov; 30(5):2270-8. PubMed ID: 23969757
[TBL] [Abstract][Full Text] [Related]
13. Promoter hypermethylation profile of kidney cancer.
Dulaimi E; Ibanez de Caceres I; Uzzo RG; Al-Saleem T; Greenberg RE; Polascik TJ; Babb JS; Grizzle WE; Cairns P
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):3972-9. PubMed ID: 15217927
[TBL] [Abstract][Full Text] [Related]
14. Genetic and epigenetic alterations affecting PARK-2 expression in cervical neoplasm among North Indian patients.
Naseem A; Bhat ZI; Kalaiarasan P; Kumar B; Gandhi G; Rizvi MMA
Tumour Biol; 2017 Jun; 39(6):1010428317703635. PubMed ID: 28631565
[TBL] [Abstract][Full Text] [Related]
15. Integrated analysis of DNA methylation profiling and gene expression profiling identifies novel markers in lung cancer in Xuanwei, China.
Wang J; Duan Y; Meng QH; Gong R; Guo C; Zhao Y; Zhang Y
PLoS One; 2018; 13(10):e0203155. PubMed ID: 30286088
[TBL] [Abstract][Full Text] [Related]
16. 5'-CpG island methylation of the FHIT gene is associated with reduced protein expression and higher clinical stage in cervical carcinomas.
Wu Q; Shi H; Suo Z; Nesland JM
Ultrastruct Pathol; 2003; 27(6):417-22. PubMed ID: 14660280
[TBL] [Abstract][Full Text] [Related]
17. Two-hit inactivation of FHIT by loss of heterozygosity and hypermethylation in breast cancer.
Yang Q; Nakamura M; Nakamura Y; Yoshimura G; Suzuma T; Umemura T; Shimizu Y; Mori I; Sakurai T; Kakudo K
Clin Cancer Res; 2002 Sep; 8(9):2890-3. PubMed ID: 12231533
[TBL] [Abstract][Full Text] [Related]
18. Repression of MAL tumour suppressor activity by promoter methylation during cervical carcinogenesis.
Overmeer RM; Henken FE; Bierkens M; Wilting SM; Timmerman I; Meijer CJ; Snijders PJ; Steenbergen RD
J Pathol; 2009 Nov; 219(3):327-36. PubMed ID: 19662663
[TBL] [Abstract][Full Text] [Related]
19. Allele loss and promoter hypermethylation of VHL, RAR-beta, RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma.
Kuroki T; Trapasso F; Yendamuri S; Matsuyama A; Alder H; Mori M; Croce CM
Cancer Res; 2003 Jul; 63(13):3724-8. PubMed ID: 12839965
[TBL] [Abstract][Full Text] [Related]
20. Identification of diagnostic markers in colorectal cancer via integrative epigenomics and genomics data.
Kok-Sin T; Mokhtar NM; Ali Hassan NZ; Sagap I; Mohamed Rose I; Harun R; Jamal R
Oncol Rep; 2015 Jul; 34(1):22-32. PubMed ID: 25997610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
